Stay updated on Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page.

Latest updates to the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page
- ChecktodayChange DetectedThe footer’s ClinicalTrials.gov site revision label changes from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe ClinicalTrials.gov page footer now displays revision v3.8.0 instead of v3.7.2.SummaryDifference0.1%

- Check29 days agoChange DetectedA site-wide NIH notice was added announcing a transition from using “Artificial Intelligence” to “Super Intelligence” in some federal-agency content.SummaryDifference0.5%

- Check36 days agoChange DetectedThe site footer now displays revision v3.7.2 instead of v3.7.1.SummaryDifference0.1%

- Check42 days agoChange DetectedThe ClinicalTrials.gov page footer now identifies the site as revision v3.7.1 instead of v3.7.0.SummaryDifference0.1%

- Check64 days agoChange DetectedThe history now lists a new version (v3.7.0) and removes the previous (v3.6.6), representing an update to the recorded history rather than a change to the trial data.SummaryDifference0.1%

Stay in the know with updates to Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page.